Uppsala 20th February 2020


Good results in study with peptides

Nanexa, together with one of the companies conducting the evaluation of PharmaShell®, has now obtained positive results in an animal study where PharmaShell® was used to formulate peptides. In the study, two different variants of PharmaShell® were evaluated and the results of the study showed, as we expected, that we greatly extend the release of peptide and that the initial release was markedly limited.

Nanexa’s CEO David Westberg comments:

These are really great results that we obtained together with the partner company in this study. Results that are important for the continuation of the collaboration but also because we once again demonstrate the possibility of using PharmaShell® with peptides in general.


For further information:

Nanexa AB (publ)

David Westberg, VD

Phone: +46 709 42 83 03

E mail: david.westberg@nanexa.se



About Nanexa AB (publ)

Nanexa AB is a nanotechnology drug delivery company focusing on the development of PharmaShell®, which is a new and groundbreaking drug delivery system that is expected to have great potential in a number of medical indications. Within the framework of PharmaShell®, Nanexa has partnership agreements with among others, AstraZeneca.